Historical Stock Chart
2 Months : From Nov 2019 to Jan 2020
By Sabela Ojea
AstraZeneca PLC (AZN.LN) said Friday that a supplemental biologics license application and granted priority review for the Imfinzi drug, which fights against untreated extensive-stage small-cell lung cancer, has been accepted by the U.S. Food and Drug Administration.
The drug maker said a prescription-drug user fee act date--the deadline for the FDA to review the application--is set for the first quarter of 2020.
Small-cell lung cancer is an aggressive, fast-growing form of lung cancer that recurs and progresses rapidly, the London-listed company said.
Write to Sabela Ojea at email@example.com; @sabelaojeaguix
(END) Dow Jones Newswires
November 29, 2019 02:28 ET (07:28 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.